"Very much fun", "Great camaradie", "Wonderful spirit" - Such voices were heard many at this year's John Goldman Fun Run. In good old tradition, a group of about 40 participants started the day very early at 7 am on Sunday morning to participate in the Foundation’s annual charity Fun Run at the John Goldman Conference on CML.
Chairs: T. Cortes, T.P. Hughes, D.S. Krause
Speakers at this meeting will present the newest and often unpublished data that relate to the;
1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI
2) Aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells and approaches to cure.
Registration for the meeting is now open. To register go to the ESH website.
The preliminary scientific program is now available here.
The 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden is now up. To help you plan your CML meeting schedule we have compiled a list of all CML related sessions for your convenience. Updates will follow soon as they become available on the EHA website.
From 12-15 October 2017 more than 439 clinicians and scientists from 43 different countries attended the annual John Goldman Conference on CML in Estoril.
“The fact that this meeting takes place for the 19th time this year tells a lot about the passion of the CML scientific community to constantly improving the management of patients with CML and to better understanding the biology of CML”, said Jorge Cortes during the opening ceremony.
As in previous years the scientific sessions focused on various aspects related to the biology and management of CML including; signal transduction pathways involved in CML, possible mechanisms of genomic instability, leukemia stem cells and it's relationship to disease kinetics, challenges of monitoring individual patients with hematologic, cytogenetic and molecular methods, role of allogeneic stem cell transplantation in the management of CML, possible role of different immunotherapeutic approaches in CML, treatment-free survival as an endpoint in CML management and patient reported outcomes and their role in the management of CML patients.
You can view a summary of the scientific program from the perspective of the meeting chairman,Professor Jorge Cortes here.
Early in the morning at 7am, before the Sunday sessions and just a few hours before the Lisbon marathon passed by, participants of the 19th John Goldman Conference on CML – all dressed up in green ‘John Goldman Fun Run’ T-Shirts – started to run along the beautiful Estoril promenade. Despite the early hour everyone had a big smile in their faces enjoying the sea view and the sunrise.
Again this year, all this was for a good cause: by purchasing a bright green ‘iCMLf John Goldman Fund’ running T-Shirt participants supported the training of young physicians from the emerging regions.
From 15-18 September 2016 more than 370 clinicians and scientists from 33 different countries gathered at the Annual John Goldman Conference on CML in Houston to present the newest and often unpublished data related to the biology and clinical management of CML. ‘John Goldman started this conference as a very small meeting a few years ago that has now evolved into one of the most important meetings for scientists and clinicians interested in CML who take each year a lot of new ideas and inspiration from this meeting', said Jorge Cortes during the opening session. Professor Jorge chaired the meeting together with Professor Tessa Holyoake and Professor Tim Hughes.